A kit for evaluating the effectiveness of adalimumab in treating psoriasis based on 78 SNP loci
Through a kit based on 78 SNP sites, specific genetic mutations in psoriasis patients are detected and personalized adalimumab treatment plans are provided, which solves the uncertainty and economic burden of treating psoriasis in the prior art. , improves the therapeutic effect and applicability to Asian populations.
Patent Information
- Application Number
- CN202310058466.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-29
- Filing Date
- 2023-01-18
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-01-18
AI Technical Summary
The existing research on adalimumab in treating psoriasis lacks systematicity, especially for Asian populations, which leads to different response rates in patients and a high financial burden.
A kit based on 78 SNP sites is provided to detect whether psoriasis patients carry specific mutation sites, and evaluate Adad by PCR amplification, alkaline phosphatase treatment, single-base extension and MALDI-TOF analysis The effectiveness of muzumab in the treatment of psoriasis is particularly suitable for Asian populations.
By identifying specific SNP loci variants in Asian populations, personalized treatment recommendations are provided, the therapeutic effect of adalimumab is improved, the financial burden on patients, and more accurate treatment guidance is provided for patients with psoriasis.
Smart Images

Figure BDA0004060869920000041 
Figure BDA0004060869920000051 
Figure BDA0004060869920000061
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and more specifically, to a kit for evaluating the effectiveness of adalimumab in treating psoriasis based on 78 SNP sites. Background Art
[0002] Psoriasis is a multi-gene hereditary disease. To treat psoriasis, adalimumab has appeared on the market. Adalimumab is a fully human IgG1 antibody to TNF-α. Adalimumab binds to free TNF-α, blocking the interaction between TNF-α and TNF-α receptors on the cell surface, thereby regulating TNF-α-induced or regulated responses.
[0003] In the process of adalimumab treatment of psoriasis, patients with different mutation genes show different response rates. In order to achieve precise treatment, let patients take fewer detours in treatment, and thus reduce the economic burden of patients, this application searches through public databases and finds that there are currently many articles analyzing the response rate of patients with different mutation genes to adalimumab drugs, but they lack systematic evaluation and have low guiding significance for psoriasis patients. In addition, these studies are mainly aimed at European and American populations, and there is no clear guidance for Asian populations. Summary of the invention
[0004] An object of the present invention is to solve at least the above problems and to provide at least the advantages which will be described hereinafter.
[0005] Another object of the present invention is to provide 78 SNP sites on which adalimumab acts, and the provided 78 SNP sites are more suitable for Asian populations and have guiding significance for Asian populations;
[0006] Also provided is an application of 78 SNP sites on which adalimumab acts in evaluating the effectiveness of adalimumab in treating psoriasis, where when a patient carries one or more variant sites among the 78 SNP sites, it indicates that the use of adalimumab is effective;
[0007] Also provided is a kit for evaluating the effectiveness of adalimumab in treating psoriasis based on 78 SNP sites, which contains a set of single-stranded DNAs for detecting whether psoriasis patients carry the 78 SNP sites, and the set of single-stranded DNAs consists of single strands SEQID No. 1 to 234 in the sequence table.
[0008] In order to achieve these purposes and other advantages according to the present invention, 78 SNP sites for adalimumab are provided, and the 78 SNP sites include: rs2071303 site, rs28371759 site, rs1801274 site, rs3761847 site, rs1800795 site, rs352139 site, rs2145623 site, rs33980500 site, rs4810485 site, rs3794271 site, rs396991 site, rs10903129 site, rs2546890 site, rs510432 site, rs1295686 site, rs885814 site, and rs10 43879, rs3735451, rs10210302, rs17301249, rs6427528, rs548234, rs27524, rs1061622, rs2736340, rs17716942, rs6920220, rs394581, rs9373839, rs2476601, rs1061624, rs2734440, rs6691117, rs10499194, rs2246709, rs35599367, rs2812378 point, rs1799852, rs7527798, rs11586238, rs11209026, rs3218253, rs767455, rs240993, rs20575, rs10512734, rs8049439, rs2104286, rs12081765, rs645544, rs13393173, rs3087243, rs12721622, rs2228145, rs1350948, rs1267067, rs7234029, rs47 50316 site, rs7927894 site, rs2302489 site, rs1980422 site, rs7574865 site, rs9828223 site, rs1126535 site, rs10919563 site, rs3213094 site, rs9304742 site, rs2230926 site, rs610604 site, rs6822844 site, rs13031237 site, rs3814057 site, rs6661932 site, rs4646437 site, rs2740574 site, rs1130864 site, rs12777960 site, and rs25648 site.
[0009] Application of 78 SNP sites of adalimumab action in evaluating the effectiveness of adalimumab in the treatment of psoriasis.
[0010] A kit for evaluating the effectiveness of adalimumab in treating psoriasis based on 78 SNP sites, wherein the material used to detect whether a psoriasis patient carries the 78 SNP sites is a kit containing a set of single-stranded DNA, wherein the set of single-stranded DNA consists of single strands of SEQ ID No. 1 to 234 in the sequence list.
[0011] A method for using a kit for evaluating the effectiveness of adalimumab in treating psoriasis based on 78 SNP sites comprises the following specific steps:
[0012] S1. Extracting DNA from the peripheral blood of patients with psoriasis to obtain DNA to be tested;
[0013] S2, amplifying the DNA to be tested by PCR technology to obtain PCR amplification products;
[0014] S3, treating the PCR product with alkaline phosphatase to obtain a treated PCR product;
[0015] S4, performing single base extension on the obtained processed PCR product to obtain an extended product;
[0016] S5, purifying the obtained extension product to obtain a purified product;
[0017] S6. Place the purified product on a detector to detect whether the psoriasis patient carries one or more of the 78 SNP sites that are affected by adalimumab.
[0018] Preferably, the specific detection process in step S6 is to first place the purified product on a SpectroCHIP chip, analyze the SpectroCHIP chip using MALDI-TOF, and type the detection results using TYPER software and output the results.
[0019] Preferably, the concentration of the collected DNA in step S1 is adjusted to 50 ng / μL and stored at -20°C for future use.
[0020] The present invention has at least the following beneficial effects:
[0021] First, it provides 78 SNP sites for the action of adalimumab, which are more suitable for Asian populations and have guiding significance for Asian populations;
[0022] Second, it provides an application of 78 SNP sites on which adalimumab acts in evaluating the effectiveness of adalimumab in treating psoriasis. When a patient carries one or more variant sites among the 78 SNP sites, it indicates that adalimumab is effective for the patient.
[0023] Third, a kit for evaluating the effectiveness of adalimumab in treating psoriasis based on 78 SNP sites is provided, which contains a set of single-stranded DNAs for detecting whether psoriasis patients carry 78 SNP sites, and the set of single-stranded DNAs consists of single strands of SEQ ID No. 1 to 234 in the sequence list.
[0024] Other advantages, objectives and features of the present invention will be embodied in part through the following description, and in part will be understood by those skilled in the art through study and practice of the present invention. DETAILED DESCRIPTION
[0025] The present invention is further described in detail below in conjunction with embodiments so that those skilled in the art can implement the invention with reference to the description.
[0026] The invention provides 78 SNP sites for adalimumab, and the 78 SNP sites include: rs2071303 site, rs28371759 site, rs1801274 site, rs3761847 site, rs1800795 site, rs352139 site, rs2145623 site, rs33980500 site, rs4810485 site, rs3794271 site, rs396991 site, rs10903129 site, rs2546890 site, rs510432 site, rs1295686 site, rs885814 site, rs1043879 site, rs37 35451, rs10210302, rs17301249, rs6427528, rs548234, rs27524, rs1061622, rs2736340, rs17716942, rs6920220, rs394581, rs9373839, rs2476601, rs1061624, rs2734440, rs6691117, rs10499194, rs2246709, rs35599367, rs2812378, rs1799 852, rs7527798, rs11586238, rs11209026, rs3218253, rs767455, rs240993, rs20575, rs10512734, rs8049439, rs2104286, rs12081765, rs645544, rs13393173, rs3087243, rs12721622, rs2228145, rs1350948, rs1267067, rs7234029, rs475031 6 sites, rs7927894 sites, rs2302489 sites, rs1980422 sites, rs7574865 sites, rs9828223 sites, rs1126535 sites, rs10919563 sites, rs3213094 sites, rs9304742 sites, rs2230926 sites, rs610604 sites, rs6822844 sites, rs13031237 sites, rs3814057 sites, rs6661932 sites, rs4646437 sites, rs2740574 sites, rs1130864 sites, rs12777960 sites, and rs25648 sites.
[0027] The above 78 SNP sites are of guiding significance to the Asian population, among which rs28371759, rs3735451, rs2246709, rs35599367, rs12721622, rs4646437 and rs2740574 are new SNP sites found by the present invention, and these new SNP sites are more suitable for the Asian population.
[0028] The present invention provides an application of 78 SNP sites on which adalimumab acts in evaluating the effectiveness of adalimumab in treating psoriasis. When a patient carries one or more variant sites among the 78 SNP sites, it indicates that the use of adalimumab is effective.
[0029] The present invention provides a kit for evaluating the effectiveness of adalimumab in treating psoriasis based on 78 SNP sites, wherein the material for detecting whether a psoriasis patient carries the 78 SNP sites is a kit containing a set of single-stranded DNAs, wherein the set of single-stranded DNAs is composed of single-stranded DNAs of SEQ ID No. 1 to 234 in the sequence table, and the 234 single-stranded DNAs include PCR primer pairs for amplifying gene fragments of the 78 SNP sites, and 78 corresponding Sequenom MassARRAY single-base extension primers for specifically detecting the genotypes of the 78 SNP sites, as shown in Table 1.
[0030]
[0031]
[0032]
[0033]
[0034] How to use the kit:
[0035] S1. 2 mL of blood was collected from the body of a psoriasis patient using an EDTA anticoagulant tube, and genomic DNA was extracted from the collected blood using a commercial kit. The extracted DNA was quantified using a spectrophotometer and the quality of the DNA was checked by agarose gel electrophoresis. The concentration of the qualified DNA was adjusted to 50 ng / μL and stored at -20°C for future use to obtain the DNA to be tested;
[0036] S2. PCR amplification is performed on the DNA to be tested, wherein the primers are as shown in Table 1, and the amplification technology is performed in a 384-well plate, the total volume of the liquid in each well plate is 5 μL, and each well plate contains 20-50 ng DNA, 0.5 pmol of each amplification primer, and 0.1 μL of 25 mM dNTPs. The PCR reaction conditions are: 94°C for 4 min; 94°C for 20 s, 56°C for 30 s, 72°C for 1 min, 45 cycles; 72°C for 3 min; 4°C maintained, to obtain PCR amplification products;
[0037] S3. Treat the PCR amplification product with shrimp alkaline phosphatase (SAP) to remove free dNTPs in the reaction system. The SAP reaction system is 7 μL, which includes 5 μL of PCR product and 2 μL of SAP mixed solution (SAP 0.5U, buffer 0.17 μL). Use a PCR instrument to treat with shrimp alkaline phosphatase. The PCR reaction conditions are: 37°C for 40 min, 85°C for 5 min, and 4°C to obtain the treated PCR product.
[0038] S4. The treated PCR product was subjected to single base extension. The total volume of the reaction system was 9 μL, including 7 μL of treated PCR product, 2 μL of EXTEND Mix (0.94 μL of primers, 0.04 μL of iPLEX enzyme, and 0.2 μL of extension mixture). The PCR reaction conditions were as follows: Ⅰ 94°C 30 s; Ⅱ 94°C 5 s; Ⅲ 52°C 5 s; Ⅳ 80°C 5 s; Ⅴ go to Ⅲ 4 more times; Ⅵ go to Ⅱ 39 more times; Ⅶ 72°C 3 min, 4°C forever, to obtain the extended product.
[0039] S5, spread the Clean Resin resin on a 6 mg resin plate, then place the extension product in the well of the resin plate, add 16 μL of water to the well containing the extension product, and finally add the dried resin to the well containing the extension product, seal the film, and rotate the resin plate vertically at a low speed for 30 minutes to allow the resin in the well to fully contact the extension product, then centrifuge to allow the vertical resin to sink to the bottom of the well, and the purified product obtained floats on the upper layer;
[0040] S6. First, place the purified product on the SpectroCHIP chip, analyze the SpectroCHIP chip using MALDI-TOF, and use TYPER software to type and output the test results.
[0041] <Example>
[0042] 1. The present invention was used to perform gene testing on 19 patients with moderate to severe psoriasis. The gene mutations of these patients are shown in Table 1.
[0043] Table 1
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052] Note: ID is the SNP site, REF is the reference genome information, PSA is the psoriasis patient number, 0 means no SNP mutation occurs, and 1 means SNP mutation occurs.
[0053] 2. According to the test results, the number of mutation sites detected in the above patients is shown in Table 2;
[0054] Table 2 Number of mutation sites in patients
[0055]
[0056]
[0057] 3. We recommended adalimumab treatment for patients with psoriasis, with a dosing regimen of 40 mg subcutaneously injected once every two weeks, before treatment (PASI-0) and after 3 months of treatment (PASI-3). The PSAI (Psoriasis Area and Severity Index) score was used to evaluate the skin lesions of patients with psoriasis, and then measure the efficacy of adalimumab in treating psoriasis. The results are shown in Table 3. PASI scores of patients with psoriasis before and after treatment.
[0058] Psoriasis efficacy evaluation criteria: According to the Psoriasis Area and Severity Index (PASI) scoring criteria, the PASI scores before and after treatment were recorded, and the efficacy was evaluated based on the PASI score reduction rate. PASI score reduction rate = (PASI score before treatment - PASI score after treatment) / PASI score before treatment x 100%.
[0059] Table 3. PASI scores of psoriasis patients before and after treatment
[0060]
[0061] By analyzing the reduction rate of PASI scores in psoriasis patients three months after treatment, we found that the skin lesions of these patients improved (PASI scores decreased).
[0062] 4. The ASA (Asian Screening Array) whole genome chip commonly used in GWAS studies was used to sequence and analyze the genomic DNA of 10,000 Chinese Han people with psoriasis and 10,000 control people. The genomic variation sites associated with adalimumab were then analyzed in detail. The sites with differences are shown in Table 4: Genomic variation associated with adalimumab in Chinese Han people with psoriasis
[0063] Table 4 Genomic variations associated with adalimumab in psoriasis in Chinese Han population
[0064]
[0065]
[0066]
[0067]
[0068]
[0069] Note: CHR chromosome number; BP physical position; A1 reference allele; Allele reference is gene frequency; F_A: frequency of the first base in Allere; F_U: frequency of the second base in Allere.
[0070] Table 4 summarizes that the 78 SNPs involved in the present invention have a significant correlation with the occurrence of psoriasis in Chinese Han people, with P_value < 0.01.
[0071] 5. As can be seen from Table 1, the above 19 patients have mutations at seven sites: rs28371759, rs3735451, rs2246709, rs35599367, rs12721622, rs4646437, and rs2740574. In order to further prove that psoriasis patients carrying only these seven mutation sites will also have a good effect when undergoing adalimumab treatment, the following experiments were conducted:
[0072] By testing the genes of a large number of patients with psoriasis, we found cases with mutations in one or more of these seven sites, as shown in Table 5 below:
[0073] Table 5 Genotyping of psoriasis patients
[0074]
[0075]
[0076]
[0077]
[0078] 5. The patients in Table 5 were given medication in the same treatment method as in Example 3. The results are shown in Table 6:
[0079] Table 6 PASI scores of psoriasis patients before and after treatment
[0080]
[0081] As can be seen from Table 6, adalimumab has a good therapeutic effect on patients with mutations in one or more of the rs28371759 site, rs3735451 site, rs2246709 site, rs35599367 site, rs12721622 site, rs4646437 site, and rs2740574 site shown in Table 4.
[0082] Although the embodiments of the present invention have been disclosed as above, they are not limited to the applications listed in the specification and the implementation modes, and they can be fully applied to various fields suitable for the present invention. For those familiar with the art, additional modifications can be easily implemented. Therefore, without departing from the general concept defined by the claims and the scope of equivalents, the present invention is not limited to the specific details and the illustrations shown and described herein.
Claims
1. Use of a reagent for detecting SNP sites in the preparation of a kit for evaluating the effectiveness of adalimumab in treating psoriasis, characterized in that: The reagent is used to detect whether a psoriasis patient carries 7 SNP sites, wherein the SNP sites are: rs28371759 site, rs3735451 site, rs2246709 site, rs35599367 site, rs12721622 site, rs4646437 site, and rs2740574 site. The reagent consists of SEQ ID No. 4-6, SEQ ID No.52-54, SEQ ID No.103-105, SEQ ID No.106-108, SEQ ID No.157-159, SEQ ID No.220-222, and SEQID No.223-225 in the sequence list.
